Business Description
Egetis Therapeutics AB
NAICS : 325412
SIC : 2834
ISIN : SE0003815604
Compare
Compare
Traded in other countries / regions
EGTX.Sweden0ABW.UKP0F.Germany IPO Date
2017-12-08Description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.33 | |||||
| Beneish M-Score | -3.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.3 | |||||
| 3-Year EBITDA Growth Rate | 20.2 | |||||
| 3-Year EPS without NRI Growth Rate | 18.5 | |||||
| 3-Year FCF Growth Rate | 16.4 | |||||
| 3-Year Book Growth Rate | -19 | |||||
| Future 3-5Y Total Revenue Growth Rate | 145.16 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.28 | |||||
| 9-Day RSI | 55.13 | |||||
| 14-Day RSI | 57.36 | |||||
| 6-1 Month Momentum % | -7.3 | |||||
| 12-1 Month Momentum % | -6.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.98 | |||||
| Quick Ratio | 0.98 | |||||
| Cash Ratio | 0.78 | |||||
| Days Inventory | 1.09 | |||||
| Days Sales Outstanding | 126.57 | |||||
| Days Payable | 38.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.6 | |||||
| Shareholder Yield % | -4.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -205.15 | |||||
| Operating Margin % | -446.18 | |||||
| Net Margin % | -469.56 | |||||
| FCF Margin % | -316.52 | |||||
| ROE % | -72.39 | |||||
| ROA % | -49.61 | |||||
| ROIC % | -59.35 | |||||
| ROC (Joel Greenblatt) % | -7345.77 | |||||
| ROCE % | -56.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 35.68 | |||||
| PS Ratio | 28.79 | |||||
| PB Ratio | 6.11 | |||||
| EV-to-EBIT | -8.03 | |||||
| EV-to-Forward-EBIT | 5.77 | |||||
| EV-to-EBITDA | -8.03 | |||||
| EV-to-Forward-EBITDA | 5.77 | |||||
| EV-to-Revenue | 34.86 | |||||
| EV-to-Forward-Revenue | 2.52 | |||||
| EV-to-FCF | -10.97 | |||||
| Earnings Yield (Greenblatt) % | -12.45 | |||||
| FCF Yield % | -9.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egetis Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.042 | ||
| EPS (TTM) (€) | -0.098 | ||
| Beta | 1.89 | ||
| Volatility % | 73.72 | ||
| 14-Day RSI | 57.36 | ||
| 14-Day ATR (€) | 0.022649 | ||
| 20-Day SMA (€) | 0.52705 | ||
| 12-1 Month Momentum % | -6.36 | ||
| 52-Week Range (€) | 0.338 - 0.79 | ||
| Shares Outstanding (Mil) | 359.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egetis Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egetis Therapeutics AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Egetis Therapeutics AB Frequently Asked Questions
What is Egetis Therapeutics AB(STU:P0F)'s stock price today?
The current price of STU:P0F is €0.54. The 52 week high of STU:P0F is €0.79 and 52 week low is €0.34.
When is next earnings date of Egetis Therapeutics AB(STU:P0F)?
The next earnings date of Egetis Therapeutics AB(STU:P0F) is 2025-02-21 Est..
Does Egetis Therapeutics AB(STU:P0F) pay dividends? If so, how much?
Egetis Therapeutics AB(STU:P0F) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers